Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: results from the calm study by the cmwp of the ebmt - Université de Lille Accéder directement au contenu
Article Dans Une Revue European Journal of Haematology Année : 2021

Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: results from the calm study by the cmwp of the ebmt

Giulia Sbianchi
  • Fonction : Auteur
Simona Iacobelli
  • Fonction : Auteur
J. L. Byrne
  • Fonction : Auteur
Peter Remenyi
  • Fonction : Auteur
Jane F. Apperley
  • Fonction : Auteur
Cecilia Isaksson
  • Fonction : Auteur
Paul Browne
  • Fonction : Auteur
Jiri Mayer
  • Fonction : Auteur
Stig Lenhoff
  • Fonction : Auteur
Soledad Gonzalez Muniz
  • Fonction : Auteur
Rocio Parody Porras
  • Fonction : Auteur
Grzegorz W. Basak
  • Fonction : Auteur
Xavier Poire
  • Fonction : Auteur
Marek Trneny
  • Fonction : Auteur
Arnon Nagler
  • Fonction : Auteur
Mariagrazia Michieli
  • Fonction : Auteur
Alina Tanase
  • Fonction : Auteur
Linda Koster
  • Fonction : Auteur
Patrick J. Hayden
  • Fonction : Auteur
Meral Beksac
  • Fonction : Auteur
Stefan O. Schonland
  • Fonction : Auteur

Résumé

BACKGROUND: In autologous stem cell transplant (ASCT)-eligible myeloma patients, prolonged induction does not necessarily improve the depth of response. METHODS: We analyzed 1222 ASCT patients who were classified based on (a) the interval between induction and stem cell collection, (b) the type of induction regimen: BID (Bortezomib, IMiDs, and Dexamethasone), Bortezomib-based, or CTD (Cyclophosphamide, Thalidomide, and Dexamethasone), and (c) the time to best response (Early ie, best response within 4 or 5 months, depending on the regimen vs Late; Good ie, VGPR or better vs Poor). RESULTS: The length of induction treatment required to achieve a Good response did not affect PFS (P = .65) or OS (P = .61) post-ASCT. The three types of regimen resulted in similar outcomes: median PFS 31, 27.7 and 30.8 months (P = .31), and median OS 81.7, 92.7, and 77.4 months, respectively (P = .83). On multivariate analysis, neither the type nor the duration of the induction regimen affected OS and PFS, except for Early Good Responders who had a better PFS compared to Early Poor Responders (HR = 1.21, P-value = .02). However, achieving a Good response at induction was associated with a better response (≥VGPR) post-transplant. CONCLUSIONS: The kinetics of response did not affect outcomes.
Fichier non déposé

Dates et versions

hal-04488765 , version 1 (04-03-2024)

Identifiants

Citer

Laurent Garderet, Giulia Sbianchi, Simona Iacobelli, Didier Blaise, J. L. Byrne, et al.. Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: results from the calm study by the cmwp of the ebmt. European Journal of Haematology, 2021, European Journal of Haematology, ⟨10.1111/ejh.13602⟩. ⟨hal-04488765⟩
7 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More